{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:55:43Z","timestamp":1791309343664,"version":"4.3.1"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.leukres.2026.108337","type":"journal-article","created":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:07:35Z","timestamp":1791151655000},"page":"108337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Momelotinib induces hemoglobin improvement and symptom control in PCM1::JAK2-associated myeloid neoplasm"],"prefix":"10.1016","volume":"171","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4303-1683","authenticated-orcid":false,"given":"Tobias Ronny","family":"Haage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje-Friederike","family":"Pelz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanja","family":"Zeremski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Mougiakakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2026.108337_bib1","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108337_bib2","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2026.108337_bib3","doi-asserted-by":"crossref","first-page":"e661","DOI":"10.1093\/oncolo\/oyac072","article-title":"PCM1-JAK2 fusion tyrosine kinase gene-related neoplasia: a systematic review of the clinical literature","volume":"27","author":"Kaplan","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.leukres.2026.108337_bib4","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41379-018-0165-9","article-title":"Hematopoietic neoplasms with 9p24\/JAK2 rearrangement: a multicenter study","volume":"32","author":"Tang","year":"2019","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.leukres.2026.108337_bib5","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/ajh.25825","article-title":"Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes","volume":"95","author":"Schwaab","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2026.108337_bib6","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","article-title":"SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-Na\u00efve patients with myelofibrosis","volume":"35","author":"Mesa","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2026.108337_bib7","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","article-title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study","volume":"401","author":"Verstovsek","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2026.108337_bib8","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70+ version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis","volume":"36","author":"Tefferi","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2026.108337_bib9","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2026.108337_bib10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2020-139936","article-title":"Clinical significance of emergent leukocytosis in patients with myelofibrosis receiving JAK inhibitor therapy","volume":"136","author":"Vasic","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108337_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.753842","article-title":"Diagnosis and treatment of myeloproliferative neoplasms with PCM1-JAK2 rearrangement: case report and literature review","volume":"11","author":"Sun","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.leukres.2026.108337_bib12","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00277-014-2221-y","article-title":"Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes","volume":"94","author":"Schwaab","year":"2015","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2026.108337_bib13","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.6004\/jnccn.2020.0042","article-title":"Myeloid\/lymphoid neoplasms with eosinophilia and TK fusion genes, version 3.2021, NCCN clinical practice guidelines in oncology","volume":"18","author":"Gerds","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.leukres.2026.108337_bib14","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood.2024028000","article-title":"Role of allo-HCT in \"nonclassical\" MPNs and MDS\/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT","volume":"145","author":"Polverelli","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108337_bib15","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.bbmt.2019.02.019","article-title":"Comparison of outcomes of allogeneic transplantation for primary myelofibrosis among hematopoietic stem cell source groups","volume":"25","author":"Murata","year":"2019","journal-title":"Biol. Blood Marrow Transplant."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626001815?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626001815?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:40:58Z","timestamp":1791308458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212626001815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":15,"alternative-id":["S0145212626001815"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108337","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Momelotinib induces hemoglobin improvement and symptom control in PCM1::JAK2-associated myeloid neoplasm","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108337","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108337"}}